Country Club Bank Has $3.07 Million Holdings in Pfizer Inc. (NYSE:PFE)

Country Club Bank decreased its position in Pfizer Inc. (NYSE:PFE) by 1.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 105,639 shares of the biopharmaceutical company’s stock after selling 1,779 shares during the quarter. Country Club Bank’s holdings in Pfizer were worth $3,073,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Olistico Wealth LLC acquired a new position in Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer in the second quarter valued at $29,000. Quarry LP acquired a new stake in Pfizer in the 2nd quarter valued at $31,000. Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth about $34,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on PFE shares. Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Finally, Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Trading Down 0.6 %

Shares of Pfizer stock opened at $28.46 on Friday. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The stock has a market cap of $161.27 billion, a PE ratio of -61.87, a PEG ratio of 1.01 and a beta of 0.67. The firm has a 50-day moving average of $29.07 and a 200-day moving average of $28.49. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.90%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is currently -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.